Agilent Acquires ACEA Biosciences for $250 Million

Cleary Gottlieb is representing Agilent Technologies Inc. (Agilent) in connection with its $250 million all-cash acquisition of ACEA Biosciences Inc. (ACEA).

The transaction was announced on September 25, 2018. Closing of the transaction is conditional upon the receipt of antitrust approval. For more information, please see Agilent’s official press release here.

Founded in 2002, ACEA is a pioneer in the development and commercialization of high performance cell analysis platforms for life science research. ACEA is headquartered in San Diego and has a large manufacturing and R&D footprint in Hangzhou, China.

Agilent is a global leader in life sciences, diagnostics, and applied chemical markets. The acquisition of ACEA allows Agilent to add a differentiated portfolio and organizational capabilities in the fast-growing cell analysis market and to expand its footprint in China.